ethyl 2-hydroxy-4-methyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazine-7-carboxylate | 852233-82-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶嗪类
• 英文名称: ethyl 2-hydroxy-4-methyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazine-7-carboxylate
• 英文别名: ethyl 3,4-dihydro-2-hydroxy-4-methyl-3-oxo-2H-1,4-benzoxazine-7-carboxylate；Ethyl 2-hydroxy-4-methyl-3-oxo-1,4-benzoxazine-7-carboxylate
• CAS: 852233-82-0
• 化学式: C₁₂H₁₃NO₅
• 分子量: 251.239
• InChiKey: GOOMILIZKMVZRY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  76.1
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  ethyl 2-hydroxy-4-methyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazine-7-carboxylate 在 potassium fluoride 、 sodium hydroxide 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 生成 2-[(4-cyanobenzyl)oxy]-4-methyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazine-7-carboxylic acid
  参考文献：
  名称：

  Toward a Novel Class of Antithrombotic Compounds with Dual Function. Discovery of 1,4-Benzoxazin-3(4H)-one Derivatives Possessing Thrombin Inhibitory and Fibrinogen Receptor Antagonistic Activities

  摘要：

  A novel class of potential antithrombotic compounds with moderate thrombin inhibitory and fibrinogen receptor antagonistic activity is described. Combination of anticoagulant and antiaggregatory activity in the same molecular entity is presented as a new promising approach in the search for novel antithrombotic agents.

  DOI：

  10.1021/jm048984g
• 作为产物：
  描述：

  ethyl 4-[(2,2-dichloroacetyl)amino]-3-hydroxybanzoate 在 碳酸氢钠 、 potassium carbonate 作用下， 以 丙酮 为溶剂， 反应 1.0h， 生成 ethyl 2-hydroxy-4-methyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazine-7-carboxylate
  参考文献：
  名称：

  Toward a Novel Class of Antithrombotic Compounds with Dual Function. Discovery of 1,4-Benzoxazin-3(4H)-one Derivatives Possessing Thrombin Inhibitory and Fibrinogen Receptor Antagonistic Activities

  摘要：

  A novel class of potential antithrombotic compounds with moderate thrombin inhibitory and fibrinogen receptor antagonistic activity is described. Combination of anticoagulant and antiaggregatory activity in the same molecular entity is presented as a new promising approach in the search for novel antithrombotic agents.

  DOI：

  10.1021/jm048984g

文献信息

• Ring Opening of 2-(Benzylamino)-2H-1,4-benzoxazin-3(4H)-ones and 2-Bromo-2H-1,4-benzoxazin-3(4H)-ones
  作者：Janez Ilaš、Danijel Kikelj

  DOI：10.1002/hlca.200890069

  日期：2008.4

  Substituted 2-(benzylamino)-2H-1,4-benzoxazin-3(4H)-ones are unstable under alkaline and acidic conditions, undergoing opening of the benzoxazinone ring. 2-Bromo-2H-1,4-benzoxazin-3(4H)-ones show similar degradation under alkaline conditions, while replacement of Br at C(2) to give 2-hydroxy-2H-1,4-benzoxazin-3(4H)-ones was observed only under mild alkaline conditions. Mechanisms of ring opening and degradation

  取代的2-（苄氨基）-2 H -1,4-苯并恶嗪-3（4 H）-在碱性和酸性条件下不稳定，并经历苯并恶嗪酮环的打开。2-Bromo-2 H -1,4-苯并恶嗪-3（4 H）-在碱性条件下表现出相似的降解，而在C（2）处取代Br则得到2-羟基-2 H -1,4-苯并恶嗪仅在弱碱性条件下观察到-3（4 H）-one。提出了开环和降解为2-氨基苯酚衍生物的机理。
• [EN] ANTITHROMBOTIC COMPOUNDS WITH DUAL FUNCTION<br/>[FR] COMPOSES ANTITHROMBOTIQUES A FONCTION DUALE
  申请人：UNIV LJUBLJANA

  公开号：WO2005051934A1

  公开（公告）日：2005-06-09

  The present invention comprises compounds of the general formula (I) : and pharmaceutically acceptable salts thereof, wherein the substituents have in the description specified meaning. The compounds are used as antithrombotic agents possessing inhibitory activity on platelet aggregation and simultaneous thrombin and/or factor Xa inhibititory activity.

  本发明包括一般式(I)的化合物及其药学上可接受的盐，其中取代基具有描述中指定的含义。这些化合物被用作抗血栓药物，具有抑制血小板聚集和同时抑制凝血酶和/或因子Xa的活性。
• 3,4-Dihydro-2<i>H</i>-1,4-benzoxazine Derivatives Combining Thrombin Inhibitory and Glycoprotein IIb/IIIa Receptor Antagonistic Activity as a Novel Class of Antithrombotic Compounds with Dual Function
  作者：Janez Ilaš、Žiga Jakopin、Tina Borštnar、Mojca Stegnar、Danijel Kikelj

  DOI：10.1021/jm8003448

  日期：2008.9.25

  3,4-Dihydro-2H-1,4-benzoxazine derivatives possessing both thrombin inhibitory and glycoprotein IIb/IIIa (GPIIb/IIIa) receptor antagonistic activities were obtained by combining mimetics of the D-Phe-Pro-Arg pharmacophore of thrombin inhibitors and the Arg-Gly-Asp pharmacophor of GPIIb/IIIa receptor antagonists in the same low molecular weight peptidomimetic compound. Systematic variation of the position of substituents around the 3,4-dihydro-2H-1,4-benzoxazine nucleus, the distance between the carboxylate and amidine moieties, together with additional substituents to fill the thrombin S-2 and S-3 pockets resulted in compounds displaying submicromolar inhibition constants (K-i) for thrombin and submicromolar IC50 for inhibition of binding of fibrinogen to platelet GPIIb/IIIa receptor. Some of these compounds, such as 17a, 17b, 17d, and 17h possessing a well balanced activity at both targets, are a good starting point for further optimization. Incorporation of anticoagulant and platelet antiaggregatory activity in the same molecule constitutes a promising approach toward novel antithrombotic agents.